Clinical Trials Browser

Not yet recruiting × Fulvestrant × 90 days × Clear all

NCT07480681 2026-03-18

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

Phase 1 Not yet recruiting

Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT07389733 2026-03-02

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Phase 1/2 Not yet recruiting

Advanced Unresectable or Metastatic Breast Cancer of Adults

NCT07426822 2026-02-24

SAFE-CAP

Phase 2 Not yet recruiting

Diarrhea, Exanthema

NCT07393321 2026-02-06

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07340619 2026-01-14

EPIBREAST

Phase 2 Not yet recruiting

Melanoma, Neoplasm Metastasis

NCT07333937 2026-01-12

NETHER

Phase 2 Not yet recruiting

Brest Cancer

NCT06849947 2025-12-24

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Phase 2 Not yet recruiting

Breast Cancer Metastatic